NextCure Free Cash Flow Operating Cash Flow Ratio from 2010 to 2024
| NXTC Stock | USD 1.17 0.03 2.50% |
Free Cash Flow Operating Cash Flow Ratio | First Reported 2010-12-31 | Previous Quarter 1.01547929 | Current Value 1.2 | Quarterly Volatility 0.3669199 |
Check NextCure financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among NextCure's main balance sheet or income statement drivers, such as Discontinued Operations of 0.0, Depreciation And Amortization of 3.2 M or Interest Expense of 6.4 M, as well as many indicators such as Price To Sales Ratio of 14.65, Dividend Yield of 0.0 or PTB Ratio of 0.29. NextCure financial statements analysis is a perfect complement when working with NextCure Valuation or Volatility modules.
NextCure | Free Cash Flow Operating Cash Flow Ratio |
Latest NextCure's Free Cash Flow Operating Cash Flow Ratio Growth Pattern
Below is the plot of the Free Cash Flow Operating Cash Flow Ratio of NextCure over the last few years. It is NextCure's Free Cash Flow Operating Cash Flow Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in NextCure's overall financial position and show how it may be relating to other accounts over time.
| Free Cash Flow Operating Cash Flow Ratio | 10 Years Trend |
|
Free Cash Flow Operating Cash Flow Ratio |
| Timeline |
NextCure Free Cash Flow Operating Cash Flow Ratio Regression Statistics
| Arithmetic Mean | 1.38 | |
| Geometric Mean | 1.33 | |
| Coefficient Of Variation | 26.59 | |
| Mean Deviation | 0.33 | |
| Median | 1.69 | |
| Standard Deviation | 0.37 | |
| Sample Variance | 0.13 | |
| Range | 1.0746 | |
| R-Value | (0.75) | |
| Mean Square Error | 0.06 | |
| R-Squared | 0.56 | |
| Significance | 0 | |
| Slope | (0.06) | |
| Total Sum of Squares | 1.88 |
NextCure Free Cash Flow Operating Cash Flow Ratio History
About NextCure Financial Statements
NextCure stakeholders use historical fundamental indicators, such as NextCure's Free Cash Flow Operating Cash Flow Ratio, to determine how well the company is positioned to perform in the future. Although NextCure investors may analyze each financial statement separately, they are all interrelated. For example, changes in NextCure's assets and liabilities are reflected in the revenues and expenses on NextCure's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in NextCure. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Free Cash Flow Operating Cash Flow Ratio | 1.02 | 1.20 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether NextCure offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of NextCure's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Nextcure Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Nextcure Stock:Check out the analysis of NextCure Correlation against competitors. For information on how to trade NextCure Stock refer to our How to Trade NextCure Stock guide.You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NextCure. If investors know NextCure will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NextCure listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.10) | Quarterly Revenue Growth (1.00) | Return On Assets (0.31) | Return On Equity (0.55) |
The market value of NextCure is measured differently than its book value, which is the value of NextCure that is recorded on the company's balance sheet. Investors also form their own opinion of NextCure's value that differs from its market value or its book value, called intrinsic value, which is NextCure's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NextCure's market value can be influenced by many factors that don't directly affect NextCure's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between NextCure's value and its price as these two are different measures arrived at by different means. Investors typically determine if NextCure is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NextCure's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.